Centrexion Therapeutics changes its mind on initial public offering
The Boston-based company said it would not pursue a planned IPO, citing "market conditions." Nasdaq had agreed to its listing on Tuesday.
Centrexion’s $67M Series D round to fund Phase 3 pain studies
Despite being just four years old, Centrexion, which just raised $67 million, is building a significant pipeline of non-opioid, non-steroidal pain medications.
Where Will AI Deployment Benefit Payers the Most?
We are taking a look at how health insurers are using AI, defining success, and managing cybersecurity risks. Give us your opinions by completing our brief, anonymous survey.
Centrexion nabs three non-opioid pain drugs from Boehringer Ingelheim
Boehringer Ingelheim offloaded the drugs, it said in a statement. because it's shifting away from pain medications to focus on CNS diseases like Alzheimer's, schizophrenia and depression.